126 related articles for article (PubMed ID: 8106293)
21. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.
Sun X; Yang Z; Li S; Tan Y; Zhang N; Wang X; Yagi S; Yoshioka T; Takimoto A; Mitsushima K; Suginaka A; Frenkel EP; Hoffman RM
Cancer Res; 2003 Dec; 63(23):8377-83. PubMed ID: 14678999
[TBL] [Abstract][Full Text] [Related]
22. A genetically modified recombinant tumor necrosis factor-alpha conjugated to the distal terminals of liposomal surface grafted polyethyleneglycol chains.
Savva M; Duda E; Huang L
Int J Pharm; 1999 Jul; 184(1):45-51. PubMed ID: 10425350
[TBL] [Abstract][Full Text] [Related]
23. Modification of TNF-alpha pharmacokinetics in SA-1 tumor-bearing mice.
Kus B; Sersa G; Novaković S; Urbancic J; Stalc A
Int J Cancer; 1993 Aug; 55(1):110-4. PubMed ID: 8344743
[TBL] [Abstract][Full Text] [Related]
24. The use of PVP as a polymeric carrier to improve the plasma half-life of drugs.
Kaneda Y; Tsutsumi Y; Yoshioka Y; Kamada H; Yamamoto Y; Kodaira H; Tsunoda S; Okamoto T; Mukai Y; Shibata H; Nakagawa S; Mayumi T
Biomaterials; 2004 Jul; 25(16):3259-66. PubMed ID: 14980420
[TBL] [Abstract][Full Text] [Related]
25. Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor.
Hu B; Du HJ; Yan GP; Zhuo RX; Wu Y; Fan CL
Drug Deliv; 2014 May; 21(3):204-12. PubMed ID: 24117028
[TBL] [Abstract][Full Text] [Related]
26. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity.
Yamamoto Y; Tsutsumi Y; Yoshioka Y; Nishibata T; Kobayashi K; Okamoto T; Mukai Y; Shimizu T; Nakagawa S; Nagata S; Mayumi T
Nat Biotechnol; 2003 May; 21(5):546-52. PubMed ID: 12665803
[TBL] [Abstract][Full Text] [Related]
27. PEGylation alleviates the non-specific toxicities of Alpha-Momorcharin and preserves its antitumor efficacy in vivo.
Deng NH; Wang L; He QC; Zheng JC; Meng Y; Meng YF; Zhang CJ; Shen FB
Drug Deliv; 2016; 23(1):95-100. PubMed ID: 24786488
[TBL] [Abstract][Full Text] [Related]
28. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate.
Yang Z; Sun X; Li S; Tan Y; Wang X; Zhang N; Yagi S; Takakura T; Kobayashi Y; Takimoto A; Yoshioka T; Suginaka A; Frenkel EP; Hoffman RM
Cancer Res; 2004 Aug; 64(16):5775-8. PubMed ID: 15313919
[TBL] [Abstract][Full Text] [Related]
29. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
30. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects.
Nieforth KA; Nadeau R; Patel IH; Mould D
Clin Pharmacol Ther; 1996 Jun; 59(6):636-46. PubMed ID: 8681488
[TBL] [Abstract][Full Text] [Related]
31. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model.
Katre NV; Knauf MJ; Laird WJ
Proc Natl Acad Sci U S A; 1987 Mar; 84(6):1487-91. PubMed ID: 3494243
[TBL] [Abstract][Full Text] [Related]
32. Enhanced antitumor effect of recombinant human tumor necrosis factor in combination with recombinant human granulocyte colony-stimulating factor in BALB/c mice.
Maeda M; Watanabe N; Tsuji N; Tsuji Y; Okamoto T; Sasaki H; Akiyama S; Niitsu Y
Jpn J Cancer Res; 1993 Aug; 84(8):921-7. PubMed ID: 7691787
[TBL] [Abstract][Full Text] [Related]
33. Preparation and properties of sterically stabilized hexadecylphosphocholine (miltefosine)-liposomes and influence of this modification on macrophage activation.
Zeisig R; Eue I; Kosch M; Fichtner I; Arndt D
Biochim Biophys Acta; 1996 Sep; 1283(2):177-84. PubMed ID: 8809097
[TBL] [Abstract][Full Text] [Related]
34. Targeting of tumor necrosis factor to tumor by use of dextran and metal coordination.
Tabata Y; Noda Y; Matsui Y; Ikada Y
J Control Release; 1999 May; 59(2):187-96. PubMed ID: 10332053
[TBL] [Abstract][Full Text] [Related]
35. Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity.
Malik F; Delgado C; Knüsli C; Irvine AE; Fisher D; Francis GE
Exp Hematol; 1992 Sep; 20(8):1028-35. PubMed ID: 1505637
[TBL] [Abstract][Full Text] [Related]
36. Selective enhancement by tumor necrosis factor-alpha of vascular permeability of new blood vessels induced with agarose hydrogel-entrapped Meth-A fibrosarcoma cells.
Okada N; Kaneda Y; Miyamoto H; Yamamoto Y; Mizuguchi H; Tsutsumi Y; Nakagawa S; Mayumi T
Jpn J Cancer Res; 1996 Aug; 87(8):831-6. PubMed ID: 8797889
[TBL] [Abstract][Full Text] [Related]
37. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins.
Richter AW; Akerblom E
Int Arch Allergy Appl Immunol; 1983; 70(2):124-31. PubMed ID: 6401699
[TBL] [Abstract][Full Text] [Related]
38. PRINT: A Protein Bioconjugation Method with Exquisite N-terminal Specificity.
Sur S; Qiao Y; Fries A; O'Meally RN; Cole RN; Kinzler KW; Vogelstein B; Zhou S
Sci Rep; 2015 Dec; 5():18363. PubMed ID: 26678960
[TBL] [Abstract][Full Text] [Related]
39. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors.
Frishman JI; Edwards CK; Sonnenberg MG; Kohno T; Cohen AM; Dinarello CA
J Infect Dis; 2000 Dec; 182(6):1722-30. PubMed ID: 11069245
[TBL] [Abstract][Full Text] [Related]
40. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol.
Hershfield MS; Chaffee S; Koro-Johnson L; Mary A; Smith AA; Short SA
Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7185-9. PubMed ID: 1714590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
